延迟补充养作为维生素K缺乏症的危险因素 在9个月大的婴儿中出血
Ponni G Jayan1, Sheeja Sugunan, Devakumar V Krishnannair
1Department of Pediatrics, SAT Hospital, Government Medical College, Thiruvananthapuram, Kerala, India.
Journal of pediatric hematology/oncology
|December 8, 2025
概括
维生素K缺乏症出血 (VKDB) 在3个月后很少发生,即使进行了预防. 没有补充食品的长期母乳养可能是晚期VKDB的危险因素,需要及时干预.
科学领域:
- 儿科 儿科 儿科
- 血液学 血液学 血液学
- 新生儿科学 新生儿科学
背景情况:
- 维生素K缺乏症出血 (VKDB) 通常在生命的第一个星期表现出来.
- 晚期发病的VKDB超过3个月时异常罕见,特别是在接受常规维生素K预防的婴儿中.
- 内出血是与VKDB相关的严重并发症.
研究的目的:
- 报告一个罕见的3个月以上的婴儿大规模内出血病例.
- 强调在典型的新生儿期之外考虑VKDB的重要性.
- 在看似健康的婴儿中识别潜在的风险因素.
主要方法:
- 一个婴儿出现大规模内出血的案例报告.
- 血液检查的分析,包括凝血概况和由维生素K缺乏引起的蛋白质 (PIVKAII).
- 对维生素K和新鲜冷血 (FFP) 的治疗反应的评估.
主要成果:
- 婴儿出现了严重的贫血和失调的凝血概况,PIVKAII.II升高.
- 凝血参数在维生素K和FFP给药后12小时内迅速正常化.
- 婴儿没有吸收不良问题,除了长期纯母乳养之外,没有其他风险因素.
结论:
- 在新生儿期以外有大量出血的婴儿,特别是那些推迟引入补充料的婴儿,应该考虑VKDB.
- 长期纯母乳养可能是晚期VKDB的危险因素.
- 及时诊断和维生素K的治疗对于管理VKDB至关重要.
相关概念视频
Vitamins
2.3K
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
2.3K
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
231
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
231
Drug Dosing: Infants and Children
234
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
234
Pharmacokinetics in Pediatric Patients: Drug Distribution
244
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
244


